Literature DB >> 27177488

More Extensive Surgery May Not Improve Survival Over Parathyroidectomy Alone in Parathyroid Carcinoma.

Stephanie Young1, James X Wu1, Ning Li2, Michael W Yeh1, Masha J Livhits3.   

Abstract

BACKGROUND: Parathyroid carcinoma is a rare cause of hyperparathyroidism. Surgery is the only effective therapy, and en bloc resection has previously been recommended.
METHODS: A retrospective cohort study of patients with parathyroid carcinoma in the California Cancer Registry and California Office of Statewide Health Planning and Development database from 1999 to 2012 was performed. Patients were stratified by surgical procedure: parathyroidectomy alone, thyroid resection with en bloc parathyroidectomy, and parathyroidectomy with delayed thyroid resection within 6 months. The primary outcome was overall survival stratified by surgical procedure. Secondary outcomes included perioperative complications within 30 days of initial surgery and disease-related complications.
RESULTS: Among our study cohort (n = 136), 60 patients underwent parathyroidectomy alone, 58 patients had en bloc resection, and 18 patients had parathyroidectomy followed by delayed thyroid resection. For the entire cohort, the 5-year and 10-year overall survival rates were 86.9 and 72.0 %. The overall survival rates did not differ between the surgical procedures. Factors that were independently associated with decreased survival included age (hazard ratio 1.05, P = 0.017) and distant metastases (hazard ratio 4.73, P = 0.017), while en bloc resection and delayed thyroid resection were not associated with improved survival over parathyroidectomy alone. There were no differences in perioperative or disease-related complications across procedures.
CONCLUSIONS: The addition of thyroid resection to parathyroidectomy may not improve survival for patients with parathyroid carcinoma over complete parathyroid resection alone. A larger prospective study is necessary to determine the optimal treatment to achieve long-term survival with minimal complications.

Entities:  

Mesh:

Year:  2016        PMID: 27177488     DOI: 10.1245/s10434-016-5256-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

Review 1.  Persistent and recurrent hyperparathyroidism.

Authors:  Carole Guerin; Nunzia Cinzia Paladino; Aoife Lowery; Fréderic Castinetti; David Taieb; Fréderic Sebag
Journal:  Updates Surg       Date:  2017-04-22

2.  [Surgical treatment of parathyroid carcinoma : Does the initial en bloc resection improve the prognosis?]

Authors:  S Wächter; K Holzer; J Manoharan; C Brehm; I Mintziras; D K Bartsch; E Maurer
Journal:  Chirurg       Date:  2019-11       Impact factor: 0.955

3.  Tumor Size and Presence of Metastatic Disease at Diagnosis are Associated with Disease-Specific Survival in Parathyroid Carcinoma.

Authors:  Winifred M Lo; Meghan L Good; Naris Nilubol; Nancy D Perrier; Dhaval T Patel
Journal:  Ann Surg Oncol       Date:  2018-07-03       Impact factor: 5.344

Review 4.  Parathyroid Carcinoma: a Review.

Authors:  Shikhar Sawhney; Richa Vaish; Siddhanth Jain; Neha Mittal; Suman Kumar Ankathi; Shivakumar Thiagarajan; Devendra Chaukar
Journal:  Indian J Surg Oncol       Date:  2021-06-03

5.  Mortality factors in recurrent parathyroid cancer: a pooled analysis.

Authors:  Wen-Hsuan Tsai; Yi-Hong Zeng; Chun-Chuan Lee; Ming-Chieh Tsai
Journal:  J Bone Miner Metab       Date:  2022-02-20       Impact factor: 2.626

6.  The Use and Benefit of Adjuvant Radiotherapy in Parathyroid Carcinoma: A National Cancer Database Analysis.

Authors:  Jessica Limberg; Dessislava Stefanova; Timothy M Ullmann; Jessica W Thiesmeyer; Sarina Bains; Toni Beninato; Rasa Zarnegar; Thomas J Fahey; Brendan M Finnerty
Journal:  Ann Surg Oncol       Date:  2020-07-13       Impact factor: 5.344

7.  Local resection versus radical surgery for parathyroid carcinoma: A National Cancer Database analysis.

Authors:  Shravan Leonard-Murali; Tommy Ivanics; David S Kwon; Xiaoxia Han; Christopher P Steffes; Rupen Shah
Journal:  Eur J Surg Oncol       Date:  2021-06-27       Impact factor: 4.424

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.